N
Google TrendGME (1000+) — GameStop Stock Hits a New 52-Week High: What's Going On?
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:gme1000+pope francis200+nicolò tresoldi500+michael olise1000+bank of america fine1000+club brugge500+rb leipzig200+saudi news1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Recurrent GBM Brain Tumor" (30 stories)

Top Headline Story

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel
Lead StoryAlpha Tau Medicalworld
Jun 23

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

<a href="https://news.google.com/rss/articles/CBMijgJBVV95cUxOSnFiRV9oNlZEUkdBM25FYXEzbGlSTV9OWGtiWHNvVU9lQW9kOUhJajQyTzdET2dpNUpiY1BvUXF4U3NPMUxVSDY3Q055aTVVaTFYNGJjQy1nV2cxS0VmUGZDM29ydmxSeTVVcG5HMkRsZVE0NThfb3R2dTllUGYyRGxfT19BcnRLUzRGdVYweFN5T0ozWGgtXzFkN3pHN1JldV9fY0hGcllKMkxtV1pRTFVyQXcwQVpBVVVzNWpXYVJUdTl0TTZ2LTh2N2M1Sl9SWFhYMUVhdlJuZHpBdlY0OFotWkF2V1BhME92TUdHZlNBbHl0ckNDSWtXVGpza3lvU19fb1ZwOThhU2ZoUEE?oc=5" target="_blank">Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel</a>  <font color="#6f6f6f">Alpha Tau Medical</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
1000+24m ago

gme

GameStop Stock Hits a New 52-Week High: What's Going On?

Filter stories
200+24m ago

pope francis

The Myth of St. Francis

Filter stories
500+34m ago

nicolò tresoldi

Nicolò Tresoldi, chi è l'attaccante del Bruges che spaventa l'Inter in Champions League

Filter stories
1000+34m ago

michael olise

The Ballon d’Or doesn’t capture football’s wonder – Michael Olise is proof | Zito Madu

Filter stories

Search Results for "Recurrent GBM Brain Tumor"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Immune activation may determine success of dual-target CAR T therapy in glioblastoma
Penn Medicineworld

Immune activation may determine success of dual-target CAR T therapy in glioblastoma

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOdGl6OE54X3NXY19qTEQyX2ZtR2NyelFWcGc4cUhTRkQxLU4yNDZobjBTS1FDeFcwNUtsNm9xUEhuYTZCWFBSNWpjUjgyUjBzek9pRHZGUHNZM3llU0lsZXEzVUtSczBzSkZmMGE2VUdRTGpxRl81RFRnTVdfbzJVM2xnQnAydzl0eGE0YUpCUTNqdmVNcmI1WQ?oc=5" target="_blank">Immune activation may determine success of dual-target CAR T therapy in glioblastoma</a>  <font color="#6f6f6f">Penn Medicine</font>

Read Full StoryMore like this
Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial
Natureworld

Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE96b1VoOHFtYVpXUThwbjNoQ3NSdmx6TEpQc3c3M0R5WXVYcFlxWEtVNV9EaDU3TUREU1h2eGRibXg5YmRtUW5JaHdib2hNOUVCUVM5ZnFLdzRuck9FcThj?oc=5" target="_blank">Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
FDA Clears Alpha DaRT Trial to Complete Enrollment in Recurrent GBM
CancerNetworkgeneral

FDA Clears Alpha DaRT Trial to Complete Enrollment in Recurrent GBM

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQaWJLQVRpcWdIU180WEVsc3RsZXBJTTM4eGk3Z3RTTHhRMlhNdzZLaV9CRmRwbDdid0ZWVEtfQmN0U0tJX0dpcmxJZzNFa1RuTFpuT1RySUpKdjdmMlY2c0FUb0ZGX2tQMEM4eXd5NUNqLWk5eWxQTXBfdEJqN0hDdDdUckNEaWthYWZ4Nml2THljUUY5ajRMdnJ2Z1c?oc=5" target="_blank">FDA Clears Alpha DaRT Trial to Complete Enrollment in Recurrent GBM</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
ISRAELI FIRST: Hadassah Surgeons Treat Patient With Recurrent Glioblastoma Using Innovative Radiation Therapy
Hadassah | The Women's Zionist Organization of Americageneral

ISRAELI FIRST: Hadassah Surgeons Treat Patient With Recurrent Glioblastoma Using Innovative Radiation Therapy

<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxNb2NtRGE2OV9lZ2RRNElWRFhWQ1RaZEdzRkxXT25hNUs0UGp5eDRUS0w4RU0zLXFmbjN3SFpzWVMxTHdMMmZfTjROUDltQ2x3WkNYQnpPRVlTTHJVTHRwdGJrei1ObUl4QTJib2hpelpQTGpvUExyS3M0cTR3YWdkY3dwdHZDcmpLSVRFWkNPbF9yS1g5RUdYSVkzZlc0WGg0MTJ3Q052QVAtTzRXdS1rYlBwSlJpQi1FOE1VTVlqZF94ekZOei0zZ2k0cmZRX3VtLXg4UWxpSTJqUWJEbjlTMg?oc=5" target="_blank">ISRAELI FIRST: Hadassah Surgeons Treat Patient With Recurrent Glioblastoma Using Innovative Radiation Therapy</a>  <font color="#6f6f6f">Hadassah | The Women's Zionist Organization of America</font>

Read Full StoryMore like this
Checkpoint Inhibitors Are Failing Recurrent GBM. This Phase 1 Trial Design May Explain Why They Keep Trying.
The Clinical Trial Vanguardtech

Checkpoint Inhibitors Are Failing Recurrent GBM. This Phase 1 Trial Design May Explain Why They Keep Trying.

<a href="https://news.google.com/rss/articles/CBMi-AFBVV95cUxNLXhjYTJESzFxVzF3RXZ6dWtVRnRadVhIQTdKUFNrN1piY2Zlb1hibkdzNnpGNGRtRlhLNVllM1RVQlBKRHdudTNRODRKaDZsNV9COXZRbVpPS3oxb3Ftd09fZXJrdzNGbFBpcmJZNFR4djNSTHZlQ2FmM1FlZWFlU2N0NWNxUWdHUzhqaGV3N19peGUyNktPREdTY0FOcHZYRFJTOHMyT3BaREktRS1RZFBQbk1icmEyMkd6V1RxZWQzYjEwTFNhTG5OVFdpc3lORVQ0V1liUjJtTmVSSWdySTBQbXhWUnFyVndHekZPeWpNOXdPM3RaVA?oc=5" target="_blank">Checkpoint Inhibitors Are Failing Recurrent GBM. This Phase 1 Trial Design May Explain Why They Keep Trying.</a>  <font color="#6f6f6f">The Clinical Trial Vanguard</font>

Read Full StoryMore like this
Modern brachytherapy in glioblastoma: overcoming clinical barriers to improve local control
Frontiersgeneral

Modern brachytherapy in glioblastoma: overcoming clinical barriers to improve local control

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOT1lnQVNfaFZySGRSVnNZRUVMZDh2MFdBdGxFVTFyd2lVeE0tbEk1VEFfcC1zbC10aUZTNk8tSkNjclF3eGRUN1I1am9PODF2cUV6YUZkTnJTZmJ0bjM0eHl4UW9QeTJzNWJ0eXVWSVl2aXdvSWptRDdFXzNUM3FDdzlWWlVxY1pQMTA0RmRB?oc=5" target="_blank">Modern brachytherapy in glioblastoma: overcoming clinical barriers to improve local control</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Predicting Response to Stereotactic Radiosurgery for Recurrent Glioblastoma
Cleveland Clinicgeneral

Predicting Response to Stereotactic Radiosurgery for Recurrent Glioblastoma

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNcm1jb1dwVDQwWjBIWmxrRXJpWC1wSUM2UTQtMVRacmZNTUllRHNGY0t0UmZtUVktUUp4OHdhcUR3QjhBUU92dHRGQVNoZTB3ZG9kel9IWURJOTJ4T2FsMFBUTW9wRTNodFY3eW9rTFZtUnZ3QXBibGFwdl9oRGlZbDVIclBYZV9VUDAyRWFhTU1pYm9leTh4a0FWTDJYd0Y2XzdMUWxtU19HejJ4QkZFS213OA?oc=5" target="_blank">Predicting Response to Stereotactic Radiosurgery for Recurrent Glioblastoma</a>  <font color="#6f6f6f">Cleveland Clinic</font>

Read Full StoryMore like this
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
ImmunityBioworld

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

<a href="https://news.google.com/rss/articles/CBMingJBVV95cUxONUlldmVBSFlrcUpyZjdvS2tVZDBHVHlQUUk1OEJydWhPQzlZbVBnbkNVSHhLREUweW1MZ3R6ekxreUczS05LVkItNVQ4YXMwOEROelRLVTVqdW5IaGhmNmVxZE96RmNWUjZDVjFQUl8wQTd0OUVtS1BKR200ejdtTDl1R05Xd1JIWVN3YTdYeXJxeXNsbWxSV1dRTExZSFVYUFNWaU1scU02SVcxalFHX3plcmhfWWtmdjFyMnJwVHFIdEJTd2xPeWNWaUFHX0hqY0NCQ2pQMGJsTERnLTF0UG9KSmhCNF8wRkhFRXo0dWphNWkyUjQzUi05UG1BanZoNDU4S2s0MWRMQkE4ZENKUVcyNjgxcHFCNlZaTGdB?oc=5" target="_blank">ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy</a>  <font color="#6f6f6f">ImmunityBio</font>

Read Full StoryMore like this
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed
Alpha Tau Medicalworld

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed

<a href="https://news.google.com/rss/articles/CBMitgJBVV95cUxQQjRuTTFFOUZWOGVncmRzUGdJWnloTGdzQndaZXprMDRuNkc5ck9jY01XZVBvZUpzNkdidWx6czM2LVdGbFZPS0JzZ3laT2FoUnpGZ1JobkhQcW16TWRueG81UGltamZRVlVlNVVRNXM0OUpZZWI1VWJGejB0YkpPaF9tTG85REI5STZNYzBHVkZNMVZiQmVqNko4UnQ2VXpwd1VZbzMzUEFON1VJRWVyMmp5U1o5V0w4eHhsSFllSndZM1NpdkNfOGdlY0czdG1Scl9mUFExR0NiMWlwb3FQNUJwSFF4bFJ0UGRBLVFyWTBnVWx0UVFxN2Vac3ptMTBVV09DNW9ydlozeTAzRDBKSV9YVGVoYXZkcXdxajFqNDRSOEFYS01QNlp0bl9uNElCNDFaR21B?oc=5" target="_blank">Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed</a>  <font color="#6f6f6f">Alpha Tau Medical</font>

Read Full StoryMore like this
Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial
Naturegeneral

Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9hVDl4aW45czk3SnBRRzBwWl9pbkt1UlVKODQzNEF2eHpReXFXeVc4MndBR1J1S1NhTnlFT25JRUV0TjdnUHVXMkV3azhpN24tMmdPSlV6Q285am1Da0pN?oc=5" target="_blank">Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Glioblastoma recurrence followed by newly diagnosed small cell lung cancer: a case report on personalized concurrent chemoradiotherapy and therapeutic considerations
Frontiersworld

Glioblastoma recurrence followed by newly diagnosed small cell lung cancer: a case report on personalized concurrent chemoradiotherapy and therapeutic considerations

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPdlhPWnA3VlpLLS1sblg0aWVMQmRpdDRENDVRVGt2dEJ5UDMtd3FzVjVrNVlEOUtvMWZRVkd6VGo0Mk5NRk9XMXYyRC0ta1g0RlJQVC1KN1V4MFVGWDFPWFlHc2dHUFZicmVDZDR4ZnJsMHJ1SGZtRmtDZGlsWU1PQ3FwZDRJYUxuempWaGNR?oc=5" target="_blank">Glioblastoma recurrence followed by newly diagnosed small cell lung cancer: a case report on personalized concurrent chemoradiotherapy and therapeutic considerations</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Dual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cells
Naturegeneral

Dual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cells

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFA2NmhWU0lFU255TGtVRGtpNmU2OF85a1VyVEZXMjVqNGVPSGtPazFqc3l1aUZ4ckFfckY1cHllZ25oWWNiOGlzZW94dkJCZDZMMWhHTFpkeW10RzdzVERr?oc=5" target="_blank">Dual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cells</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
Alpha Tau Medicalworld

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

<a href="https://news.google.com/rss/articles/CBMijgJBVV95cUxPVkx6cXp3bWhXVjR3Z3ZzSFUtSy1JV1lMem1xdEhJeWRHbEwxTVcxSThaclZvMTJjRUF2cDkxbmNPNFJ6MVRGVGlYNWk4U21iR1RYdk1HQWRPWlh3MW1uS1ZfbVFHdnh1TndqTzNhZDgtSDFzXzBVT3M1UHhINzJPcjVfVFdBcHNhNEFVRkt1OGtyRUlRTWVYUU9tQTRBYlNwR0REY0NTcnh0YkkxN2d0VkpKbzFUNEhYWmNFQ1lUSnpNdnlpUzdsM0hRV3hZcUw5NldIbVQ1SDg4bVpzY0Zyc1hfR2prWjVSTjNOZFNLdnh0Rk8zTUQxZHFFdGJZZmlBRWE3TUdNQmRVR1pPd0E?oc=5" target="_blank">Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University</a>  <font color="#6f6f6f">Alpha Tau Medical</font>

Read Full StoryMore like this
The immunosuppressive tumor microenvironment in glioblastoma
Frontiersworld

The immunosuppressive tumor microenvironment in glioblastoma

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPb3hPUF9vN0pTcFJKZ09WczVIeXV3WEtwd21iSndvWUhYUk5RU0hac1J5Ukl5STh2cU9QYmJtX0pOaTYwUHU3c0FVWE9ldzlkZy0tSzduZTVJU05pYUdOak1rRXRCRUV1azdNdU83c3Fzb3hER1lPLUhoOFFtV2plMFk5VkR0SXBnMllHTVcyYTVRdw?oc=5" target="_blank">The immunosuppressive tumor microenvironment in glioblastoma</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
PLX3397 attenuated tumor growth and remodeled tumor microenvironment of recurrent glioblastoma
Naturegeneral

PLX3397 attenuated tumor growth and remodeled tumor microenvironment of recurrent glioblastoma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBsSGFUQVpoOG5TclJFbk93TElSc3IxanZ2UDRGTzJQZnZpclE0ck0zemRheXZUNHBsUnoxbFByakpmWktIOHhibEFmcEJPQ1Y3LWlFUUxYOGpyU0tzLXV3?oc=5" target="_blank">PLX3397 attenuated tumor growth and remodeled tumor microenvironment of recurrent glioblastoma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Modeling glioblastoma relapse in vitro: a critical journey from 2D models to organ-on-chip alternatives
Naturetech

Modeling glioblastoma relapse in vitro: a critical journey from 2D models to organ-on-chip alternatives

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBUQXJCdmpxeU9JeVk0b0NZQVRyVEZFNHFnUHdvOG1peEhDSkVXZ2FPZ3piWTN5cHFpNE5mTURXRHd2bFRybVFtdzhEc29XeV94QmF1QmdkTk53UVdwU3A0?oc=5" target="_blank">Modeling glioblastoma relapse in vitro: a critical journey from 2D models to organ-on-chip alternatives</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial
Naturegeneral

Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBMcWhJSFJ2SXYxRDhwVTN4MXVDVUFOR01ac3hsLUhHVk5JMlhSWWZDbVR3VlhMN1dKUnpkMFo2blJkU1ludmlFanZYazA5Q3UtdUxmb3k5anlzM0dmdlQ0?oc=5" target="_blank">Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Tumor habitat analysis using multiparametric MRI as a noninvasive correlate of longitudinal changes in telomerase activity in recurrent IDH-wildtype glioblastoma
Naturegeneral

Tumor habitat analysis using multiparametric MRI as a noninvasive correlate of longitudinal changes in telomerase activity in recurrent IDH-wildtype glioblastoma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBocmlRWmJDbE5Jb1gwalpkQWxRcm0zQXRBV0p1QUI4VXFHUWt1cXJNZVJSTjB1N2t3cFpOdzBiazhKN0hocF9fbk1KZEQ3UC1VRzR1RGVaRUY1YzI0RFBz?oc=5" target="_blank">Tumor habitat analysis using multiparametric MRI as a noninvasive correlate of longitudinal changes in telomerase activity in recurrent IDH-wildtype glioblastoma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Bevacizumab enhances overall survival in newly diagnosed glioblastoma patients with high COX-2 expression
Naturegeneral

Bevacizumab enhances overall survival in newly diagnosed glioblastoma patients with high COX-2 expression

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBKYi0xLWpQU3RMb1Vpd0Q5WTFtejQybVp3bkc2RzA2RUkzTHBWTU1BVmJVZ01yWjM2Mjh1c3YyUVhURGREZkJSSVVoYkdtdjEzUTlpeEptNlpMNHhYaTZJ?oc=5" target="_blank">Bevacizumab enhances overall survival in newly diagnosed glioblastoma patients with high COX-2 expression</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Mechanistic and Translational Insights of CARv3-TEAM-E in Glioblastoma
CancerNetworkgeneral

Mechanistic and Translational Insights of CARv3-TEAM-E in Glioblastoma

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQeTZmaGQwRXBkYTZuMHBSQWNad2NsaUxRNkpEbTJjS2lFanVPT2dOOTRfdERTYmZWT1F3OHUtQmxmVWJORTJleFE0cjQ5X2plVllQbGhlZHhKcndzenJON1o3QWpmeF92WnNDbU1YZzd1V21mdWdINFBESE5sNVlkNGNyRzFHeTFkY2VhTktXTkphVVJPU3NpbGVtV3RfS01JMjIwMUZtakQ?oc=5" target="_blank">Mechanistic and Translational Insights of CARv3-TEAM-E in Glioblastoma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Biomarkers predict patients with glioblastoma who will survive longer after treatment with cancer-targeting virus
UT MD Andersongeneral

Biomarkers predict patients with glioblastoma who will survive longer after treatment with cancer-targeting virus

<a href="https://news.google.com/rss/articles/CBMilAJBVV95cUxOdUFYS2NOQnJWMENjeGtZdXY2eENuNlRNbTdlRGQ3VDhTbFpkWWhqRUtkU0M4bXZIWW5VY2ZlWG05RGtxX25kMzhQWWFtdlVQNEdJdG4yWEJVOC1nWGZMZjB0bENNaHNPa3lCalRiWE1rUHBFbFBJb0lCVkwtSWVVbW5XUnJjNzZnRUZfaHYzZWJwV0RUU1ZiM3g5aFJkZXE2cmlKRVZobE1MWFdKXzRtOWxHUTNndzRDXzRrSTlKMFloUWhKZEF1cUJTQTIxUWoyZ3BTb05GMkJveUZWUmY1REV1eEZYaWtMSGJZMjluaUplS3hjQndfZWgzRnVqTDJhWDhGWVphQjNQR0pZU1NTTWtfNmc?oc=5" target="_blank">Biomarkers predict patients with glioblastoma who will survive longer after treatment with cancer-targeting virus</a>  <font color="#6f6f6f">UT MD Anderson</font>

Read Full StoryMore like this
The Top Brain Cancer News of 2025
Targeted Oncologytech

The Top Brain Cancer News of 2025

<a href="https://news.google.com/rss/articles/CBMidEFVX3lxTE16dUNZalotRXVfMUVGTU1NUlN0UTFDZ2pLUjlxZ2tGaGJ6MDNrS20tLUpwbEdxX18xaFM0Yk40VUNJWFc5c281UkxSNURrQkpiYzg0ZGFhaGNqYlZ6ZlZHeGtVNmEwcEZyRC1mLVlvbXp5a09I?oc=5" target="_blank">The Top Brain Cancer News of 2025</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Gibson Oncology, NIH to begin Phase 2 trials of LMP744 for treatment of first-time recurrent glioblastoma
Purdue Universitygeneral

Gibson Oncology, NIH to begin Phase 2 trials of LMP744 for treatment of first-time recurrent glioblastoma

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxOb2dwcU03ZElYQjFxLUNNbkd3NGZKeDBKX1pQa2sxb1k4TXVyS2ZSLU5OTURXeURJX01ic3pSeVdqQnVXVjJxanNJenZickNsVV9VZkdMLWhVQ2k5VmYyY0duWjlWZmgyN3c0OW8teWhZX2FUeHV6ckFqdldtLWZkNWt1ZFVMSVhSTzFKcWU2TUpiYWpYRU9oTkdUNEJkV2lpUUJOdl8zTks5LUhKR3FqVWNvSXRqMVZNaGU2TmhwUWtjS2I2STJvM1NUMVlSOVFFU2NZZkZNbm44VVMz?oc=5" target="_blank">Gibson Oncology, NIH to begin Phase 2 trials of LMP744 for treatment of first-time recurrent glioblastoma</a>  <font color="#6f6f6f">Purdue University</font>

Read Full StoryMore like this
‘Low tech’ chemotherapy nanoparticles show promise for deadly brain tumor recurrence
Fierce Biotechtech

‘Low tech’ chemotherapy nanoparticles show promise for deadly brain tumor recurrence

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOdFJZeXhNZU5NZ2RCN3hNY2k4Wm9zblo5UlMxdVJGSUVqVHloSWQ1c0xtVkpsdEhJMUlCUTVlai1VSTNubWlZZV9UN21pQWV1bHlqSmllSHBZbm5PbTNtdTF5NVhoY0pYcjFhWENXOHVZSGdDLVEycTg0VmoyUm8wOVlLTi1weGd6a000aTlUZ2UyMjFLVnRoblRQYWpJQWl3LWVMVGxjMUoxTnJPczB3dlF5Y0pYQ0k?oc=5" target="_blank">‘Low tech’ chemotherapy nanoparticles show promise for deadly brain tumor recurrence</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
Local therapeutic platform prevents postsurgical GBM recurrence by diminishing GICs and reshaping immunosuppressive microenvironment
Natureworld

Local therapeutic platform prevents postsurgical GBM recurrence by diminishing GICs and reshaping immunosuppressive microenvironment

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE96eHhtMVhwd05UbHlCdEtRT0FOWWhkeFdPbmhWV2U3b3F1dHZ4dXdJak51dkw2T0laS1hCTTRBSkFESTFIempscnNMUUpvcUI1N3VadzVGbEtyeFJiRmZB?oc=5" target="_blank">Local therapeutic platform prevents postsurgical GBM recurrence by diminishing GICs and reshaping immunosuppressive microenvironment</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Hadassah hospital performs first-ever experimental treatment for brain cancer
The Jerusalem Posttech

Hadassah hospital performs first-ever experimental treatment for brain cancer

<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5xc0FvZ2RZV0g3RGliZkFOTjhGLWRzUmpyQ0ZjYktiWVVzVEZxX0wzN2FsNUR3aWdhVTFzclBBWk5SZnFRZ3hMYUR0V0NxcEd6dzRsMTRCS1VucHd5Rm1qT2xZLUtQRFE?oc=5" target="_blank">Hadassah hospital performs first-ever experimental treatment for brain cancer</a>  <font color="#6f6f6f">The Jerusalem Post</font>

Read Full StoryMore like this
Alpha Tau first treats glioblastoma patient outside the U.S. in Israel
Stock Titangeneral

Alpha Tau first treats glioblastoma patient outside the U.S. in Israel

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNYlhmTHFWMWMtQkVCN1l1N1lJU2FlRnVwVXg0bEZPWkQ2ZlhZT0lISHZXenlNTW9Ib29Nc1NnUVFCVy13UE9yNmROZVdMNjcyc1kxTmNka0NHbERDajVJa0Zmbng4R2gyV0F4YnZYZjJid1lDS1lKckNKV1N2Q25saVcyMEpvdm0zdXVQRWV2Z1RQc0lmNVBzQmFJLUZjT3o2MWladi16WDF5NTRhbHdJUDJaX19RYnMwMGtQY25R?oc=5" target="_blank">Alpha Tau first treats glioblastoma patient outside the U.S. in Israel</a>  <font color="#6f6f6f">Stock Titan</font>

Read Full StoryMore like this
This virus therapy supercharges the immune system against brain cancer
Science Dailytech

This virus therapy supercharges the immune system against brain cancer

<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE1wN2ltT0xYalAyZ2xBTkhNTVJPZ2tud0N2QllWMXZ5UkZnN2htdUEzRktuZnR5VUdtUHBqYjBHZ3ZjaTFrdE1ldEFqR3VMeTlNYzZYNEVvSGNaWXkwZEpPc0pVY3RPLTF2cWQ5SjhHZw?oc=5" target="_blank">This virus therapy supercharges the immune system against brain cancer</a>  <font color="#6f6f6f">Science Daily</font>

Read Full StoryMore like this
Korean gene therapy shows early signs of activity in recurrent glioblastoma
Korea Biomedical Reviewgeneral

Korean gene therapy shows early signs of activity in recurrent glioblastoma

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFBXdXlHR3RjellRVG0tMEtoUTR2VTdSNDhNT0xhYXBQLUEtWWFGd094Z1JoVFR1RklVc1JRNUNicnh2RkgxVTRoMDBTeVJNNldHMFlpNEs4WGlyRmU4LTlSMTZZMzNtRlNkZXBtSGh30gFyQVVfeXFMUDY3NHlJcU1zVXBhVlhjdjJKazVPYVN5Qk9XLWoxajV5RkRGNzkwTHNYbmpfMTlvcWRIbXpQOUZTQnpLMV9La1JoSW9ubW1XbmdpaFZ6SXM2U3BxZXowZEN3eDZoeEc3a0xyUHdxWG5kZ1Fn?oc=5" target="_blank">Korean gene therapy shows early signs of activity in recurrent glioblastoma</a>  <font color="#6f6f6f">Korea Biomedical Review</font>

Read Full StoryMore like this
"Recurrent GBM Brain Tumor" — Live Google News Trends & Headlines